Brazil tests new chikungunya vaccine in Real-World rollout
NCT ID NCT07347002
Summary
This study aims to measure how well the VLA1553 vaccine prevents chikungunya virus disease in real-world conditions in Brazil. Researchers will compare about 1,200 people who develop chikungunya-like symptoms, checking if vaccinated individuals are less likely to test positive for the virus. The study uses existing health records from Brazilian government systems to track outcomes after people receive the single-dose vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus
Laranjeiras, Sergipe, 49060-025, Brazil
-
Fundação Faculdade Regional De Medicina De São José Do Rio Preto
São Pedro, São Paulo, 15090-000, Brazil
-
Universidade Federal Do Ceará
Fortaleza, Ceará, 60430-160, Brazil
-
Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras
Belo Horizonte, Minas Gerais, 31270-901, Brazil
Conditions
Explore the condition pages connected to this study.